These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 9846966

  • 1. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
    Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, Rassidakis A, Halazonetis TD, Field JK, Kittas C.
    Am J Pathol; 1998 Dec; 153(6):1749-65. PubMed ID: 9846966
    [Abstract] [Full Text] [Related]

  • 2. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.
    Gorgoulis VG, Koutroumbi EN, Kotsinas A, Zacharatos P, Markopoulos C, Giannikos L, Kyriakou V, Voulgaris Z, Gogas I, Kittas C.
    Mol Med; 1998 Dec; 4(12):807-22. PubMed ID: 9990866
    [Abstract] [Full Text] [Related]

  • 3. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
    Spanakis NE, Gorgoulis V, Mariatos G, Zacharatos P, Kotsinas A, Garinis G, Trigidou R, Karameris A, Tsimara-Papastamatiou H, Kouloukousa M, Manolis EN, Kittas C.
    Anticancer Res; 1999 Dec; 19(3A):1893-9. PubMed ID: 10470133
    [Abstract] [Full Text] [Related]

  • 4. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Gorgoulis VG, Zacharatos P, Kotsinas A, Mariatos G, Liloglou T, Vogiatzi T, Foukas P, Rassidakis G, Garinis G, Ioannides T, Zoumpourlis V, Bramis J, Michail PO, Asimacopoulos PJ, Field JK, Kittas C.
    Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
    [Abstract] [Full Text] [Related]

  • 5. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
    Geradts J, Fong KM, Zimmerman PV, Maynard R, Minna JD.
    Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma.
    Sano T, Hikino T, Xue Q, Saito T, Kashiwabara K, Oyama T, Nakajima T.
    Pathol Int; 2000 Sep; 50(9):709-16. PubMed ID: 11012984
    [Abstract] [Full Text] [Related]

  • 7. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
    Eymin B, Gazzeri S, Brambilla C, Brambilla E.
    Oncogene; 2002 Apr 18; 21(17):2750-61. PubMed ID: 11965548
    [Abstract] [Full Text] [Related]

  • 8. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung.
    Xue Q, Sano T, Kashiwabara K, Oyama T, Nakajima T.
    Jpn J Cancer Res; 2001 Mar 18; 92(3):285-92. PubMed ID: 11267938
    [Abstract] [Full Text] [Related]

  • 9. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity.
    Kinoshita I, Dosaka-Akita H, Mishina T, Akie K, Nishi M, Hiroumi H, Hommura F, Kawakami Y.
    Cancer Res; 1996 Dec 15; 56(24):5557-62. PubMed ID: 8971152
    [Abstract] [Full Text] [Related]

  • 10. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
    Hsu HS, Wang YC, Tseng RC, Chang JW, Chen JT, Shih CM, Chen CY, Wang YC.
    Clin Cancer Res; 2004 Jul 15; 10(14):4734-41. PubMed ID: 15269146
    [Abstract] [Full Text] [Related]

  • 11. Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas.
    Tsoli E, Gorgoulis VG, Zacharatos P, Kotsinas A, Mariatos G, Kastrinakis NG, Kokotas S, Kanavaros P, Asimacopoulos P, Bramis J, Kletsas D, Papavassiliou AG, Kittas C.
    Mol Med; 2001 Jun 15; 7(6):418-29. PubMed ID: 11474135
    [Abstract] [Full Text] [Related]

  • 12. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung.
    Xue Q, Sano T, Kashiwabara K, Saito M, Oyama T, Nakajima T.
    Pathol Int; 2002 Feb 15; 52(2):103-9. PubMed ID: 11940214
    [Abstract] [Full Text] [Related]

  • 13. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma.
    Obermann EC, Diss TC, Hamoudi RA, Munson P, Wilkins BS, Camozzi ML, Isaacson PG, Du MQ, Dogan A.
    J Pathol; 2004 Feb 15; 202(2):252-62. PubMed ID: 14743509
    [Abstract] [Full Text] [Related]

  • 14. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T.
    Clin Cancer Res; 2003 Oct 15; 9(13):4884-90. PubMed ID: 14581362
    [Abstract] [Full Text] [Related]

  • 15. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
    Le Frère-Belda MA, Gil Diez de Medina S, Daher A, Martin N, Albaud B, Heudes D, Abbou CC, Thiery JP, Zafrani ES, Radvanyi F, Chopin D.
    Hum Pathol; 2004 Jul 15; 35(7):817-24. PubMed ID: 15257544
    [Abstract] [Full Text] [Related]

  • 16. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S, Heighway J, Tschan MP, Borner MM, Altermatt HJ, Kappeler A, Tobler A, Fey MF, Thatcher N, Yarbrough WG, Betticher DC.
    Oncogene; 1998 Nov 26; 17(21):2779-85. PubMed ID: 9840942
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
    Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E.
    Oncogene; 1998 Jan 29; 16(4):497-504. PubMed ID: 9484839
    [Abstract] [Full Text] [Related]

  • 18. Alterations of CDKN2 (p16) in non-small cell lung cancer.
    de Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK, Koeffler HP.
    Genes Chromosomes Cancer; 1995 Nov 29; 14(3):164-70. PubMed ID: 8589032
    [Abstract] [Full Text] [Related]

  • 19. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas.
    Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG.
    J Pathol; 2002 Oct 29; 198(2):142-56. PubMed ID: 12237873
    [Abstract] [Full Text] [Related]

  • 20. Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status.
    Mariatos G, Gorgoulis VG, Zacharatos P, Kotsinas A, Vogiatzi T, Rassidakis G, Foukas P, Liloglou T, Tiniakos D, Angelou N, Manolis EN, Veslemes M, Field JK, Kittas C.
    Int J Cancer; 2000 Mar 20; 89(2):133-41. PubMed ID: 10754490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.